TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia
Brief Summary: An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.


Options:
A: Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4 mg Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 4 mg Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 160 mg LY2140023, 80 mg LY2140023
B: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 10 milligrams (mg) LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 milligrams (mg) LY2140023, 160 mg LY2140023, 80 mg LY2140023 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
D: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
B: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
D: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% + Hyaluronan 0.1% | Arm Label: group B; Type: EXPERIMENTAL; Interventions: Other: Inhalable Hypertonic saline 7% | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7% + Hyaluronan 0.1%; Assigned to Arm(s): group A | Intervention Type: OTHER; Name: Inhalable Hypertonic saline 7%; Assigned to Arm(s): group B
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
D: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
B: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
C: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial
Brief Summary: Rhinosinusitis disorders are almost regularly associated to Cystic Fibrosis (CF). The basic defect in CF is a dysfunction of chloride channels in exocrine glands which equally concerns upper airway mucosa. It leads to retention of secretions and consecutive chronic inflammation with bacterial superinfection.

In CF rhinosinusitis can restrict quality of life, give cause to repeated ear, nose, and throat (ENT) surgery and accelerate disease progression by bacterial acquisition into the airways.

The multicenter, randomized, double-blind, placebo-controlled, prospective clinical trial aims at the evaluation of a sino-nasal inhalation of sodium chloride 6% compared to isotonic saline with respect to ENT-related quality of life which is influenced by mucus retention and the resulting inflammation.


Options:
A: Arm Label: Dornase alfa; Type: EXPERIMENTAL; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Arm Label: isotonic saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dornase alfa (Pulmozyme), Drug: isotonic saline | Intervention Type: DRUG; Name: Dornase alfa (Pulmozyme); Assigned to Arm(s): Dornase alfa, isotonic saline | Intervention Type: DRUG; Name: isotonic saline; Assigned to Arm(s): Dornase alfa, isotonic saline
B: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
C: Arm Label: Ivacaftor Group A; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 25 mg/75 mg | Arm Label: Ivacaftor Group B; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 75 mg/150 mg | Arm Label: Ivacaftor Group C; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor 150 mg or 250 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor 25 mg/75 mg; Assigned to Arm(s): Ivacaftor Group A | Intervention Type: DRUG; Name: Ivacaftor 75 mg/150 mg; Assigned to Arm(s): Ivacaftor Group B | Intervention Type: DRUG; Name: Ivacaftor 150 mg or 250 mg; Assigned to Arm(s): Ivacaftor Group C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group
Brief Summary: Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and asymptomatic biochemical relapse

It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with Multiple Myeloma in biochemical relapse. The following must be noted:

* Patients with no formal indication for chemotherapy treatment will be included, as patients with symptomatic myeloma who after responding show biochemical relapse are generally not treated. This allows for generating both a group of patients untreated, on no additional treatment and a treatment group on zoledronic acid.
* As these are relapsing symptomatic patients, their number is far higher than patients with quiescent Multiple Myeloma. This allows for expecting a good enrolment.
* There are few reliable data on symptom progression after biochemical relapse, though it is one of the new objectives occurring in almost all clinical trials on myeloma. In the VISTA study, it has been estimated that the median time to the new treatment is 5 months (combining progression-free time and time to the next treatment). This time is much shorter than the median quiescent myeloma progression-free survival, so a very long follow-up time will not be necessary in this patient group.
* The administration of this drug to these patients can help prevent skeleton-related complications in the future, the study of which will be a secondary objective of this study.


Options:
A: Arm Label: Thalidomide + Bisphosphonate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate, Drug: Thalidomide, Drug: Zometa | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Thalidomide; Assigned to Arm(s): Thalidomide + Bisphosphonate | Intervention Type: DRUG; Name: Zometa; Assigned to Arm(s): Thalidomide + Bisphosphonate
B: Arm Label: zoledronic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: zoledronic acid | Arm Label: denosumab; Type: EXPERIMENTAL; Interventions: Biological: denosumab | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): zoledronic acid | Intervention Type: BIOLOGICAL; Name: denosumab; Assigned to Arm(s): denosumab
C: Arm Label: Zoledronate acid; Type: EXPERIMENTAL; Interventions: Drug: zoledronic acid | Arm Label: No treatment control; Type: OTHER; Interventions: Other: No treatment control | Intervention Type: DRUG; Name: zoledronic acid; Assigned to Arm(s): Zoledronate acid | Intervention Type: OTHER; Name: No treatment control; Assigned to Arm(s): No treatment control
D: Intervention Type: DRUG; Name: pamidronate; Assigned to Arm(s): N/A

Answer: C